Drug-eluting stent penetration
This article was originally published in The Gray Sheet
Executive Summary
The decline in use of drug-eluting stents in the U.S. reached a new low in the fourth quarter of 2007 - 62% of all stent placements - according to a survey of 75 hospitals by consultant Goodroe Healthcare Solutions. That figure is down from an average of 78% in Q4 of 2006 based on last year's Goodroe survey, and 75% in January (1"The Gray Sheet" Jan. 22, 2007, p. 11). The share of Johnson & Johnson/Cordis' Cypher and Boston Scientific's Taxus DES compared with bare-metal stents has held steady since September, the data shows